NCT03599063View on ClinicalTrials.gov

Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

July 30, 2018

Primary Completion Date

September 18, 2019

Study Completion Date

September 18, 2019

Conditions
Healthy
Interventions
BIOLOGICAL

PF-06946860

PF-06946860 administered subcutaneously

OTHER

Placebo

Placebo, administered subcutaneously

Trial Locations (1)

06511

Pfizer New Haven Clinical Research Unit, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03599063 - Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter